



This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. See our Form 20-F, as filed with the U.S. Securities and Exchange Commission on June 29, 2001 and the section of the Form 20-F entitled “Risk Factors”.

First milestone achieved in Centocor–Crucell agreement for CD46 human antibodies against cancer

Leiden, The Netherlands, February 1, 2002 – Dutch antibody and vaccine company Crucell N.V. (NASDAQ, Euronext Amsterdam: CRXL) today announced that the first milestone has been achieved under Crucell’s agreement with Centocor, Inc. The milestone was one of the goals that Crucell and Centocor agreed upon in their agreement for the development and commercialization of Crucell’s CD 46-specific human antibody against cancer.

The preclinical milestone further confirms the efficacy of the CD-46 antibody in animal models and indicates the development of the antibody is proceeding as planned. As a result, Centocor will make a \$1.5 million payment to Crucell.

Under the terms of the deal, Crucell has retained exclusive commercialization rights for the European Union, and will receive annual fees, milestone payments and royalties. Centocor, a Johnson & Johnson company, will be responsible for worldwide development and manufacturing.

Crucell is currently developing antibodies against colon cancer, breast cancer, anti-angiogenesis, leukemia and inflammation and has additional programs in oncology, diabetes and cardiovascular diseases. Crucell will leverage its proprietary MAbstract technology to discover new targets and antibodies.

About Crucell

Dutch biotechnology company Crucell discovers and develops novel antibodies and vaccines against cancer, inflammatory disease and infectious disease.

Crucell is currently developing antibodies against colon cancer, breast cancer, anti-angiogenesis, leukemia and inflammation and has additional programs in oncology, diabetes and cardiovascular diseases. Crucell will leverage its proprietary MAbstract technology to discover new targets and antibodies.



Crucell also plays an essential role in the development of Merck & Co.'s HIV vaccine. Merck & Co. has obtained the exclusive rights to use Crucell's PER.C6 human cell system for the production of the vaccine's key adenoviral vector. Merck & Co. is currently conducting Phase I/II trials with its vaccine.

The company has furthermore developed a revolutionary new flu vaccine production system, based on its patented human cell system PER.C6. PER.C6 is widely embraced by the industry for the production of gene therapy products and viral vectors.

Crucell has been listed on the NASDAQ and Euronext since October 2000. Crucell has its headquarters in Leiden, the Netherlands, and currently employs 199 people.

For further information please contact:

Crucell N.V.

Ilja van Roon
Communication Officer
Tel. +31-(0)71-524 8727
Fax. +31-(0) 71-524 8935
i.van.roon@crucell.com

Noonan Russo U.S.

Mary Clare Duch
Tel. +1-212-696 4455 ext.245
Fax. +1-212-696 9180
m.duch@noonanrusso.com

Noonan Russo Ltd

Veronica Sellar
Tel. +44-(0)20-7726 4452
Fax. +44-(0)20-7726 4453
v.sellar@noonanrusso.co.uk

Hill & Knowlton Nederland B.V.

Arie Bos
Tel. +31-(0)20- 404 4707
Fax.+31-(0)20 – 644 9736
abos@hillandknowlton.com